{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T21:10:52Z","timestamp":1770153052395,"version":"3.49.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":2955,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001250","name":"Morris Animal Foundation","doi-asserted-by":"publisher","award":["D10CA-004"],"award-info":[{"award-number":["D10CA-004"]}],"id":[{"id":"10.13039\/100001250","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Transitional cell carcinoma is the most common bladder cancer of dogs. Cisplatin combined with piroxicam provides superior response rates, but unacceptable rates of nephrotoxicity. Tavocept is a chemoprotectant that has mitigated cisplatin toxicity and decreased the required infusion\/diuresis volume in clinical trials in humans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>We hypothesized that Tavocept would decrease diuresis volume and time and facilitate safe administration of a cisplatin\/piroxicam protocol to dogs with bladder cancer. Secondary objectives were to compare response rate and survival times to an historical comparator group treated without Tavocept.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Fourteen client-owned dogs were prospectively enrolled.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Tumor volume was measured by computed tomography at days 0, 42, and 84. Dogs received combination Tavocept\/cisplatin with a shortened diuresis protocol. A total of 4 doses was planned, with concurrent administration of piroxicam. Serial biochemical analyses were evaluated for azotemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A 90-minute infusion\/diuresis time was used for all dogs. Three dogs (21%) had concurrent increases in serum creatinine (&amp;gt;2.0 mg\/dL) and BUN (&amp;gt;42 mg\/dL) concentrations; 2 of these dogs were isosthenuric. This frequency of nephrotoxicity is significantly less (P = 0.0406) than that of an historical control group treated without Tavocept. Overall response rate was 27%. Median survival time was comparable to historical controls (253 vs. 246 days).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Tavocept decreased the required diuresis time with cisplatin from &amp;gt; 6 hours to 90 minutes, while also decreasing occurrence of azotemia. Survival time was comparable, but the response rate was inferior to an historical comparator group. Further evaluation in other tumors susceptible to platinum agents is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.14848","type":"journal-article","created":{"date-parts":[[2017,10,28]],"date-time":"2017-10-28T00:08:41Z","timestamp":1509149321000},"page":"370-376","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Evaluation of Tavocept to Decrease Diuresis Time and Volume in Dogs with Bladder Cancer Receiving Cisplatin"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2761-5203","authenticated-orcid":false,"given":"C.J.","family":"Henry","sequence":"first","affiliation":[{"name":"College of Veterinary Medicine, University of Missouri , Columbia, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.K.","family":"Flesner","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, University of Missouri , Columbia, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.A.","family":"Bechtel","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, University of Missouri , Columbia, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.N.","family":"Bryan","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, University of Missouri , Columbia, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.J.","family":"Tate","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, University of Missouri , Columbia, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.A.","family":"Selting","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, University of Missouri , Columbia, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Lattimer","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, University of Missouri , Columbia, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.E.","family":"Bryan","sequence":"additional","affiliation":[{"name":"University of Missouri Department of Statistics, , Columbia, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Grubb","sequence":"additional","affiliation":[{"name":"TriviumVet , Waterford,","place":["Ireland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Hausheer","sequence":"additional","affiliation":[{"name":"BioNumerik Pharmaceuticals, Inc. , San Antonio, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,1,1]]},"reference":[{"key":"2026020303245210500_jvim14848-bib-0001","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0195-5616(03)00032-9","article-title":"Management of transitional cell carcinoma","volume":"33","author":"Henry","year":"2003","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"2026020303245210500_jvim14848-bib-0002","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.2460\/javma.242.11.1534","article-title":"Metronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinoma","volume":"242","author":"Schrempp","year":"2013","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303245210500_jvim14848-bib-0003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1476-5810.2005.00070.x","article-title":"Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder","volume":"3","author":"Boria","year":"2005","journal-title":"Vet Comp Oncol"},{"key":"2026020303245210500_jvim14848-bib-0004","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1939-1676.2011.00796.x","article-title":"Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder","volume":"25","author":"Arnold","year":"2011","journal-title":"J Vet Intern Med"},{"key":"2026020303245210500_jvim14848-bib-0005","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1939-1676.1994.tb03232.x","article-title":"Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder","volume":"8","author":"Knapp","year":"1994","journal-title":"J Vet Intern Med"},{"key":"2026020303245210500_jvim14848-bib-0006","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2460\/javma.239.8.1084","article-title":"Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder","volume":"239","author":"McMillan","year":"2011","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303245210500_jvim14848-bib-0007","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1939-1676.1990.tb00888.x","article-title":"Cisplatin (cisdiamminedichloroplatinum) for treatment of transitional cell carcinoma of the urinary bladder or urethra. A retrospective study of 15 dogs","volume":"4","author":"Moore","year":"1990","journal-title":"J Vet Intern Med"},{"key":"2026020303245210500_jvim14848-bib-0008","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5326\/0400131","article-title":"Piroxicam, mitoxantrone, and coarse fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs: A pilot study","volume":"40","author":"Poirier","year":"2004","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026020303245210500_jvim14848-bib-0009","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2460\/javma.241.12.1627","article-title":"Outcome of urethral stent placement for management of urethral obstruction secondary to transitional cell carcinoma in dogs: 19 cases (2007\u20132010)","volume":"241","author":"McMillan","year":"2012","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303245210500_jvim14848-bib-0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1939-1676.1997.tb00465.x","article-title":"Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder","volume":"11","author":"Chun","year":"1997","journal-title":"J Vet Intern Med"},{"key":"2026020303245210500_jvim14848-bib-0011","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s002800000147","article-title":"Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer","volume":"46","author":"Knapp","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026020303245210500_jvim14848-bib-0012","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.2460\/javma.231.7.1056","article-title":"Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder","volume":"231","author":"Greene","year":"2007","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303245210500_jvim14848-bib-0013","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.2460\/javma.1996.209.09.1588","article-title":"Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983\u20131993)","volume":"209","author":"Chun","year":"1996","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303245210500_jvim14848-bib-0014","first-page":"906","article-title":"Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma","volume":"9","author":"Henry","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2026020303245210500_jvim14848-bib-0015","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/jvim.12013","article-title":"Randomized trial of cisplatin versus firocoxib versus cisplatin\/firocoxib in dogs with transitional cell carcinoma of the urinary bladder","volume":"27","author":"Knapp","year":"2013","journal-title":"J Vet Intern Med"},{"key":"2026020303245210500_jvim14848-bib-0016","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/jsap.12009","article-title":"Retrospective evaluation of doxorubicin-piroxicam combination for the treatment of transitional cell carcinoma in dogs","volume":"54","author":"Robat","year":"2013","journal-title":"J Small Anim Pract"},{"key":"2026020303245210500_jvim14848-bib-0017","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.2460\/javma.238.8.1004","article-title":"Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder","volume":"238","author":"Marconato","year":"2011","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303245210500_jvim14848-bib-0018","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1684\/bdc.2011.1307","article-title":"Cisplatin or carboplatin, that is the question","volume":"98","author":"Moncharmont","year":"2011","journal-title":"Bull Cancer"},{"key":"2026020303245210500_jvim14848-bib-0019","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/jvim.12533","article-title":"Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs","volume":"29","author":"Allstadt","year":"2015","journal-title":"J Vet Intern Med"},{"key":"2026020303245210500_jvim14848-bib-0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1008215213739","article-title":"Carboplatin versus cisplatin in solid tumors: An analysis of the literature","volume":"9","author":"Lokich","year":"1998","journal-title":"Ann Oncol"},{"key":"2026020303245210500_jvim14848-bib-0021","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/jnci\/djk196","article-title":"Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis","volume":"99","author":"Ardizzoni","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2026020303245210500_jvim14848-bib-0022","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s00280-003-0653-5","article-title":"New approaches to drug discovery and development: A mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent","volume":"52","author":"Hausheer","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026020303245210500_jvim14848-bib-0023","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00280-010-1333-x","article-title":"Mechanistic study of BNP7787-mediated cisplatin nephroprotection: Modulation of human aminopeptidase N","volume":"67","author":"Hausheer","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026020303245210500_jvim14848-bib-0024","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0009-9236(03)00150-4","article-title":"Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites","volume":"74","author":"Verschraagen","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"2026020303245210500_jvim14848-bib-0025","doi-asserted-by":"crossref","article-title":"Accumulation of BNP7787 in human renal proximal tubule cells","author":"Hausheer","DOI":"10.1002\/jps.22510"},{"key":"2026020303245210500_jvim14848-bib-0026","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00280-009-1101-y","article-title":"Mechanistic study of BNP7787-mediated cisplatin nephroprotection: Modulation of gamma-glutamyl transpeptidase","volume":"65","author":"Hausheer","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026020303245210500_jvim14848-bib-0027","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00280-010-1340-y","article-title":"Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer","volume":"67","author":"Masuda","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026020303245210500_jvim14848-bib-0028","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/sj.bjc.6602553","article-title":"Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule","volume":"92","author":"Boven","year":"2005","journal-title":"Br J Cancer"},{"key":"2026020303245210500_jvim14848-bib-0029","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0959-8049(02)00036-9","article-title":"BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts","volume":"38","author":"Boven","year":"2002","journal-title":"Eur J Cancer"},{"key":"2026020303245210500_jvim14848-bib-0030","first-page":"1","article-title":"Comprehensive meta-analysis of survival outcomes from two randomized multicenter trials in first-line advanced non-small cell lung cancer in patients treated with the novel investigational antitumor-enhancing and chemoprotective agent Tavocept","volume":"2","author":"Hausheer","year":"2010","journal-title":"Asia-Pacific J Oncol Hematol"},{"key":"2026020303245210500_jvim14848-bib-0031","doi-asserted-by":"crossref","article-title":"Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787","author":"Parker","DOI":"10.2147\/OTT.S73690"},{"key":"2026020303245210500_jvim14848-bib-0032","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/sj.bjc.6601719","article-title":"Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats","volume":"90","author":"Verschraagen","year":"2004","journal-title":"Br J Cancer"},{"key":"2026020303245210500_jvim14848-bib-0033","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/vco.283","article-title":"Veterinary cooperative oncology group \u2013 common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1","volume":"14","year":"2016","journal-title":"Vet Comp Oncol"},{"key":"2026020303245210500_jvim14848-bib-0034","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1053\/j.seminoncol.2012.08.010","article-title":"Radiologic imaging of patients with bladder cancer","volume":"39","author":"Purysko","year":"2012","journal-title":"Semin Oncol"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.14848","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/32\/1\/370\/66672605\/jvim14848.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/32\/1\/370\/66672605\/jvim14848.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:25:02Z","timestamp":1770107102000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/32\/1\/370\/8449658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.14848","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1]]},"published":{"date-parts":[[2018,1,1]]}}}